Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Rafael Holdings, Inc. RFL

Real Estate — Real Estate Services

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
31.60%

Capital & Financial Ratios

Market Cap
107.14
Revenue
0.98
Net Income
(31.08)
Free Cash Flow
(31.92)
Net Debt
(29.89)
Current Ratio
3.16
Debt/Equity
0.01
P/E ratio
0.00
P/S ratio
107.16
P/B ratio
1.30
Past 5Y EPS Growth
(32.60%)
This Y EPS Growth
—
Next Y EPS Growth
—
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 79.51 65.94 52.77 30.50
Receivables 0.60 0.94 1.83 0.29
Inventory — — 0.28 0.28
Other 0.91 — 1.05 2.92
82.94 72.50 56.71 34.86
2023 2024 2025 Q'26
Payables 0.33 2.56 6.89 7.04
ST’ Debt — 0.61 0.61 0.61
Other 1.05 0.85 0.79 0.61
2.15 7.51 11.60 11.02
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Oct Jan Apr Jul Year
’26 0.24 0.21 0.18 —
—
’25 0.13 0.08 0.36 0.35
0.92
’24 0.07 0.07 0.34 0.17
0.64
’23 0.07 0.07 0.07 0.07
0.28
’22 0.19 0.07 0.08 0.07
0.41
’21 1.05 0.96 0.99 0.19
0.80
’20 1.21 1.24 1.22 1.24
4.91
in millions of $

Operating Cash Flow

Oct Jan Apr Jul Year
’26 (6.81) (7.52) (7.28) —
—
’25 (3.04) (2.31) (3.19) (10.38)
(18.92)
’24 (2.13) (2.53) (0.25) (2.89)
(7.80)
’23 (2.58) (5.54) (1.31) (1.45)
(10.89)
’22 (6.47) (7.34) (10.37) (1.90)
(26.08)
’21 (2.65) (2.87) (3.09) (6.98)
(15.60)
’20 (0.94) (0.96) (1.07) (1.69)
(4.67)
in millions of $

Free Cash Flow

Oct Jan Apr Jul Year
’26 (6.74) (7.53) (7.28) —
—
’25 (3.06) (2.31) (3.19) (10.38)
(18.93)
’24 (2.13) (2.54) (0.39) (2.92)
(7.98)
’23 (2.58) (5.54) (1.31) (1.45)
(10.89)
’22 (6.50) (7.34) (10.36) (1.90)
(26.08)
’21 0.86 (2.93) (3.12) (6.70)
(11.90)
’20 (1.26) (1.10) (1.11) (1.73)
(5.20)
in millions of $

EPS

Oct Jan Apr Jul Year
’26 (0.19) (0.13) (0.08) —
—
’25 (0.37) (0.19) (0.19) (0.28)
(1.04)
’24 (0.15) 0.25 (1.36) (0.19)
(1.45)
’23 0.07 (0.14) (0.06) 0.06
(0.08)
’22 (6.49) (0.12) (0.28) (0.24)
(6.31)
’21 (0.09) (0.50) (0.15) (0.75)
(1.49)
’20 (0.10) (0.08) (0.14) (0.34)
(0.66)

Target Price Range

High
—
—
Average
—
—
Low
—
—

Recommendation Rating

1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 1.58 1.42 1.27 1.12 — — —
Low Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.36 2.49 2.47 3.19 — — —
High Price
— — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 23 13 31 23 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.02 0.02 0.02 0.04 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.41 0.28 0.64 0.92 — — —
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 75.82% 85.39% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (139.97) (8.74) (67.26) (33.20) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (34,139.51%) (3,134.41%) (10,559.03%) (3,620.07%) — — —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (142.38) (2.21) (65.00) (30.64) — — —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.07 0.08 (1.67) 3.05 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.02 0.01 0.03 0.03 — — —
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.31) (0.08) (1.45) (1.04) — — —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.32) (0.47) (0.33) (0.64) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 0.00 (0.01) 0.00 — — —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.32) (0.47) (0.34) (0.64) — — —
Free CF/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.92 4.15 3.63 3.34 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.77 23.26 23.75 29.42 — — —
Shares
‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 — — —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 91.60 164.26 54.80 54.22 — — —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.39 0.47 0.40 0.51 — — —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (25.98) (66.85) (47.64) (2.57) — — —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.41 1.71 3.82 0.12 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (26.08) (10.89) (7.80) (18.92) — — —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00 — (0.18) (0.01) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (26.08) (10.89) (7.98) (18.93) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 87.32 80.80 64.99 45.11 — — —
Working Cap'
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ 15.00 — 0.69 0.69 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (48.23) (79.51) (65.25) (52.08) — — —
Net Debt
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 97.21 96.63 86.26 98.37 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (91.53%) (1.73%) (35.17%) (28.94%) — — —
ROA
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (77.18%) (54.91%) (305.36%) (39.37%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (106.59%) (1.94%) (37.63%) (33.06%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Rafael Holdings (RFL), a microcap life sciences holdco betting big on early-stage biotechs like Cyclo Therapeutics and Sensei Biotherapeutics, embodies the brutal boom-bust of the sector: revenues cratered 95% from 2017 peaks to a pitiful $279,000 in 2023 amid clinical flops and post-COVID derating, fueling $142 million impairments and a stock plunge from $65 highs to today’s $1-3 doldrums—now trading at a 36% discount to book value. Profitability remains a bloodbath, with ROE at -37% and persistent cash burn, yet a cash fortress (-$52 million net debt) and negligible capex offer rare dry powder in this dilutive graveyard (shares up 139% over the decade).

A massive 2025 insider buy—13 million shares scooped by the CEO/Chairman—screams conviction amid revenue’s modest rebound (128% YoY to $637,000 in 2024, 44% more in 2025), stabilizing margins, and pipeline catalysts like FDA nods. But is this a value trap or phoenix? Projections flag ongoing losses (-$30 million in 2025) and affiliate dependency, with sky-high PS multiples (54x) betting on inflection that history mocks. For contrarians eyeing biotech beta, RFL’s aligned insiders and asset bargain scream undervalued lottery ticket—yet one trial flop could torch it all. Dive deeper for the full risk-reward dissection.

Read full commentary →

Rafael Holdings, Inc. (RFL) Latest News

News by impact score

Fine-tune

11 Jun

4 GlobeNewswire, 7:00 AM
Rafael Holdings, Inc. reported its financial results for the third quarter of fiscal year 2025, showing a net loss of $4.8 million, a significant decrease from $32.4 million in the same period last year. The company completed a $25 million rights offering to support its merger with Cyclo Therapeutics, which is advancing a Phase 3 clinical trial for Trappsol® Cyclo™ aimed at treating Niemann-Pick Disease Type C1. Research and development expenses increased due to the merger and consolidation of Cornerstone and Day Three Labs. Total assets rose to $108.1 million, while total liabilities increased to $23.6 million. The merger with Cyclo Therapeutics and the upcoming clinical trial results are likely to significantly impact the company's future performance and investor sentiment.

3 , 7:30 AM
Rafael Holdings, Inc. released third quarter fiscal 2026 financial results. Quarterly earnings release supplies performance data that can shift near-term valuation and trading activity.

10 Jun

3 GlobeNewswire, 7:30 AM
Rafael Holdings completed last patient last visit for pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C. Phase 3 patient visit completion advances Trappsol Cyclo toward potential approval for Niemann-Pick Disease Type C.

28 Apr

3 Simply Wall St., 10:26 AM
Rafael Holdings, Inc. (RFL) insider dramatically increased holdings by 1,810% over the past year, signaling strong personal confidence in the company's prospects. Massive insider buying signals confidence and may moderately boost investor sentiment and short-term stock performance.

22 Apr

4 GlobeNewswire, 7:00 AM
Rafael Holdings, Inc. (RFL) announces patent licensing agreement with MIT for small molecules to improve myelination in ApoE4 positive Alzheimer’s Disease. Licensing MIT patents for Alzheimer’s therapeutics targeting ApoE4 enhances RFL’s biotech pipeline and positions it in a high-value market.

16 Mar

3 GlobeNewswire, 4:01 PM
Rafael Holdings, Inc. (RFL) reported second quarter fiscal 2026 financial results, detailing revenue, expenses, net income, and key operational updates. Quarterly earnings reports provide insights into financial health and operations, moderately influencing investor sentiment and stock performance.

11 Dec

3 , 4:01 PM
Rafael Holdings, Inc. reported its financial results for the first quarter of fiscal 2026, highlighting key metrics such as revenue, net income, and operational developments. The company continues to focus on its strategic initiatives and investments in biotechnology, aiming to enhance its market position. Management provided insights into future growth prospects and ongoing projects, emphasizing their commitment to innovation and shareholder value. The financial results indicate moderate changes that may influence the company's performance but are balanced by existing market conditions.

3 , 7:00 AM
Rafael Holdings, Inc. reported its first quarter fiscal 2025 financial results. The financial results may moderately influence the company's performance and competitive positioning.

19 Nov

3 , 8:58 AM
An insider at Rafael Holdings, Inc. significantly increased their stake in the company by 1,810% over the past year, indicating strong personal confidence in the company's future prospects. A substantial insider purchase suggests positive sentiment, but its overall impact on the company's trajectory remains limited.

29 Oct

3 GlobeNewswire, 4:24 PM
Rafael Holdings, Inc. reported its financial results for the fourth quarter and full year of fiscal 2025, highlighting key metrics such as revenue growth and net income. The company emphasized its strategic initiatives and ongoing investments in its core operations, which are expected to drive future growth. Management provided insights into market conditions and outlined plans for upcoming projects aimed at enhancing shareholder value. The financial results indicate moderate growth and strategic initiatives that may influence future performance.

16 Sep

4 , 8:00 AM
Rafael Holdings, Inc. announced the presentation of preliminary data from its ongoing Phase 3 TransportNPC™ open-label, single-arm sub-study involving patients under three years old. The study aims to evaluate the safety and efficacy of the TransportNPC™ platform in this young demographic, which is critical for addressing unmet medical needs in pediatric patients. Initial findings suggest promising results, potentially paving the way for further development and regulatory considerations. The preliminary data from the Phase 3 study could significantly influence the company's future product development and market positioning in pediatric therapeutics.

27 Aug

3 GlobeNewswire, 8:00 AM
Rafael Holdings, Inc. announced that abstracts have been accepted for oral and poster presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM). This event will showcase research related to inborn errors of metabolism, highlighting the company's commitment to advancing scientific knowledge in this area. Participation in a significant international congress may enhance the company's visibility and credibility in the field.

18 Jun

4 , 7:00 AM
Rafael Holdings, Inc. has announced the continuation of its Phase 3 study for the treatment of Niemann-Pick Disease Type C1 (NPC1) after an independent Data Monitoring Committee (DMC) reviewed the prespecified 48-week interim data. The DMC's review supports the ongoing clinical trial, which aims to evaluate the efficacy and safety of the treatment in patients with NPC1. The continuation of the Phase 3 study indicates significant progress in a critical treatment area, potentially impacting the company's future performance and investor sentiment.

12 Jun

4 , 9:50 AM
Rafael Holdings, Inc. (RFL) has seen a significant increase of 29% in its stock price, coinciding with a 61% rise in insider buying activity. This surge in both stock performance and insider purchases suggests growing confidence among company executives and may indicate positive future prospects for the firm. The substantial increase in stock price and insider buying signals strong confidence in the company's future performance.

4 Jun

4 GlobeNewswire, 4:01 PM
Rafael Holdings, Inc. announced the final results of its $25 million rights offering, which closed on May 29, 2025, resulting in subscriptions for 3,130,480 shares of Class B common stock at $1.28 per share, generating gross proceeds of approximately $4 million. CEO Howard Jonas and affiliates, holding about 32% of the company, did not exercise their rights but will purchase unsubscribed shares for about $21 million. The proceeds will support regulatory efforts and the potential launch of Trappsol® Cyclo™ pending positive results from a clinical trial for Niemann-Pick Disease Type C1. The company expects to have around 50.9 million Class B shares and 787,163 Class A shares outstanding post-offering. The rights offering and backstop private placement are significant financial moves that will enhance the company's capital for critical product development.

20 May

3 GlobeNewswire, 4:01 PM
Rafael Holdings, Inc. announced an update regarding its rights offering, distributing non-transferable subscription rights for its Class A and Class B common stock. Each subscription right allows holders to purchase 0.603 of a share of Class B common stock at $1.28 per share. Holders of Public Warrants received a proportional subscription right, with three warrants equating to one full right. Howard Jonas, the Executive Chairman, will enter a Standby Purchase Agreement to buy any unsubscribed shares. The offering period runs from May 13 to May 29, 2025, and is subject to certain conditions. A registration statement for the Class B common stock has been filed with the SEC. Holders are advised to consult their advisors before exercising rights. The rights offering may moderately influence financial performance and market sentiment but is not expected to fundamentally alter the company's trajectory.

5 May

4 GlobeNewswire, 7:00 AM
Rafael Holdings, Inc. announced revised subscription rights for its $25 million rights offering, allowing holders of record as of May 9, 2025, to purchase shares of Class B Common Stock at $1.28 each. The subscription period runs from May 13 to May 29, 2025. Howard Jonas, the Executive Chairman, will enter a Standby Purchase Agreement to buy any unsubscribed shares. The offering is subject to conditions and may be terminated by the company. A registration statement has been filed with the SEC, and the rights offering details will be available through D.F. King & Co., Inc. The rights offering and potential capital raise could significantly impact the company's financial position and support the development of its lead clinical candidate.

29 Apr

4 GlobeNewswire, 4:30 PM
Rafael Holdings, Inc. has announced a proposed $25 million rights offering aimed at supporting the development and potential launch of Trappsol® Cyclo™. This initiative reflects the company's commitment to advancing its product pipeline and enhancing shareholder value. The rights offering is a significant strategic move that could enhance product development and investor sentiment.

24 Apr

4 , 4:15 PM
Rafael Holdings, Inc. is intensifying its focus on the development of Trappsol® Cyclo™. Concurrently, Chief Executive Officer Bill Conkling will be stepping down from his position, signaling a potential shift in leadership as the company prioritizes its product development efforts. The leadership change and renewed focus on product development could significantly impact the company's strategic direction and market positioning.

26 Mar

4 , 6:50 AM
Rafael Holdings, Inc. has successfully completed its merger with Cyclo Therapeutics after receiving necessary shareholder approvals. This merger is expected to enhance Rafael's portfolio and strategic positioning in the biotechnology sector. The merger is a significant strategic move that could alter the company's trajectory and investor sentiment.

13 Mar

4 GlobeNewswire, 5:50 PM
Rafael Holdings, Inc. reported a net loss of $4.6 million for Q2 FY2025, compared to a net income of $6.0 million in the same period last year. The company anticipates closing its merger with Cyclo Therapeutics in Q3, focusing on Cyclo's lead clinical program, Trappsol® Cyclo™, for Niemann-Pick Disease Type C1. Cash and cash equivalents stood at $48.3 million as of January 31, 2025. Research and development expenses increased to $0.9 million, while general and administrative expenses remained stable at $2.6 million. The first six months of FY2025 showed a net loss of $13.6 million, down from a net income of $2.4 million in the previous year, primarily due to unrealized losses on investments in Cyclo. The pending merger with Cyclo Therapeutics and the focus on a promising clinical program are likely to significantly impact future performance.

4 GlobeNewswire, 5:04 PM
Rafael Holdings, Inc. reports positive financial results for the second quarter of fiscal 2024, with net income from continuing operations and increased ownership in Day Three Labs. The company's strategic investments and positive financial results are expected to significantly impact its future performance and market positioning.

6 Dec

4 Simply Wall St., 3:07 PM
BioNexus Gene Lab, Nephros, and Rafael Holdings are highlighted as top US penny stocks with potential for significant returns despite financial challenges. The article discusses significant financial challenges and strategic moves that could fundamentally alter Rafael Holdings' trajectory and investor sentiment.

6 Nov

3 , 7:14 PM
Rafael Holdings, Inc. reported its fourth quarter and full year fiscal 2024 financial results. The financial results may moderately influence the company's performance and competitive positioning.

22 Aug

4 Business Wire, 6:50 AM
Rafael Holdings and Cyclo Therapeutics have entered into a merger agreement to focus on developing Trappsol® Cyclo™ for Niemann-Pick Disease Type C1. The merger is expected to close in late 2024 pending shareholder approval. The merger agreement between Rafael Holdings and Cyclo Therapeutics is a significant strategic move that could fundamentally alter the company's trajectory and competitive positioning.

19 Jun

4 Simply Wall St., 6:43 AM
Rafael Holdings reported a net loss of US$32.4m in the third quarter of 2024, with a loss per share of US$1.36, significantly worse than the same period in 2023. The significant increase in net loss and loss per share is likely to have a major impact on Rafael Holdings' future performance and investor sentiment.

14 Jun

4 GlobeNewswire, 4:01 PM
Rafael Holdings, Inc. reported financial results for the third quarter and first nine months of fiscal 2024, showing a net loss driven by research and development expenses and investments in various pharmaceutical companies. The financial results and strategic investments mentioned in the article are likely to have a significant impact on Rafael Holdings, Inc.'s future performance and market positioning.

30 May

4 Business Wire, 9:00 AM
Cyclo Therapeutics completes enrollment of last patient in Phase 3 trial for Niemann-Pick Disease Type C1. Phase 3 trial completion and potential FDA submission could significantly impact Rafael Holdings, Inc. future.

14 Dec

3 GlobeNewswire, 4:01 PM
Rafael Holdings, Inc. reports financial results for the first quarter of fiscal 2024, focusing on advancing existing portfolio and strategic investments. The financial results and strategic investments are expected to moderately influence the company's future performance.

15 Nov

4 Business Wire, 8:05 AM
Cyclo Therapeutics reports strong enrollment in Phase 3 study for NPC1, merger with AMT on track to close before year end, and strengthens balance sheet with cash proceeds. The merger with AMT and strong enrollment in pivotal study are expected to significantly impact future performance and strategic direction of the company.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us